Raymond James Reaffirms Buy Rating for Regenxbio (RGNX)

Share on StockTwits

Raymond James reissued their buy rating on shares of Regenxbio (NASDAQ:RGNX) in a report released on Monday.

Other analysts also recently issued reports about the stock. ValuEngine downgraded shares of Regenxbio from a strong-buy rating to a buy rating in a research report on Thursday, October 11th. Barclays boosted their price target on shares of Regenxbio from $48.00 to $83.00 and gave the stock an overweight rating in a research report on Monday, August 13th. BidaskClub downgraded shares of Regenxbio from a buy rating to a hold rating in a research report on Friday, October 5th. Chardan Capital boosted their price target on shares of Regenxbio from $90.00 to $130.00 and gave the stock a buy rating in a research report on Monday, July 16th. Finally, TheStreet upgraded shares of Regenxbio from a d+ rating to a c rating in a research report on Monday, September 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. Regenxbio presently has a consensus rating of Hold and an average price target of $77.64.

Shares of NASDAQ:RGNX opened at $66.67 on Monday. Regenxbio has a fifty-two week low of $23.25 and a fifty-two week high of $85.10. The stock has a market capitalization of $1.97 billion, a P/E ratio of -27.21, a PEG ratio of 12.10 and a beta of -1.19.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.93). Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. The company had revenue of $40.03 million for the quarter, compared to the consensus estimate of $100.00 million. On average, equities analysts predict that Regenxbio will post 1.64 earnings per share for the current year.

In other news, CFO Vittal Vasista sold 7,500 shares of Regenxbio stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $65.43, for a total value of $490,725.00. Following the transaction, the chief financial officer now owns 123,584 shares of the company’s stock, valued at approximately $8,086,101.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen Yoo sold 20,414 shares of Regenxbio stock in a transaction that occurred on Monday, October 29th. The stock was sold at an average price of $62.37, for a total transaction of $1,273,221.18. Following the completion of the transaction, the insider now directly owns 20,414 shares in the company, valued at approximately $1,273,221.18. The disclosure for this sale can be found here. Insiders have sold a total of 178,167 shares of company stock worth $11,214,837 over the last 90 days. 16.90% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Regenxbio by 89.9% in the 2nd quarter. BlackRock Inc. now owns 4,218,413 shares of the biotechnology company’s stock worth $302,671,000 after purchasing an additional 1,997,447 shares during the last quarter. RTW Investments LP grew its stake in shares of Regenxbio by 10.7% in the 2nd quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock worth $149,208,000 after purchasing an additional 201,788 shares during the last quarter. Northern Trust Corp grew its stake in shares of Regenxbio by 21.2% in the 2nd quarter. Northern Trust Corp now owns 359,040 shares of the biotechnology company’s stock worth $25,762,000 after purchasing an additional 62,849 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Regenxbio by 140.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 319,330 shares of the biotechnology company’s stock worth $22,911,000 after purchasing an additional 186,595 shares during the last quarter. Finally, Botty Investors LLC grew its stake in shares of Regenxbio by 9.0% in the 3rd quarter. Botty Investors LLC now owns 224,187 shares of the biotechnology company’s stock worth $16,926,000 after purchasing an additional 18,473 shares during the last quarter. 80.91% of the stock is currently owned by institutional investors.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply